Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.

Brockmann, Rouen; Nixon, Joanna; Love, Bryan L; Yunusa, Ismaeel

Brockmann, Rouen; Nixon, Joanna; Love, Bryan L; Yunusa, Ismaeel.

Afiliação

Brockmann R; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Nixon J; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Love BL; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Yunusa I; Center for Outcomes Research and Evaluation, University of South Carolina College of Pharmacy, Columbia, USA.

Lancet Reg Health Am ; 20: 100467, 2023 Apr.

Article em En | MEDLINE | ID: mdl-36908502